Atrial fibrillation (AF) is a heart condition where the heart beats irregularly. Milvexian and apixaban are medicines that help prevent blood clots. This study compares which medicine works better in preventing strokes and other clot-related issues in people with AF. Participants need to be 18 or older and should have a stable medical condition that allows for long-term blood-thinning treatment. They should have AF and meet specific risk factors like being older than 65, having high blood pressure, diabetes, heart problems, or a history of strokes. People with certain heart valve issues cannot join. This study is important because it helps doctors know which medicine is more effective for patients with AF.

• The study involves taking medicine and monitoring its effects.
• Participants must meet specific health criteria to join.
• Potential participants should be aware of the risks and benefits of participation.